AN 2898

Drug Profile

AN 2898

Alternative Names: AN-2898

Latest Information Update: 04 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Nitriles; Organic boron compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Psoriasis

Most Recent Events

  • 07 Feb 2012 Final efficacy and adverse events data from a phase IIa trial in Atopic dermatitis released by Anacor
  • 12 Dec 2011 Preliminary efficacy data from a phase IIa trial in Atopic dermatitis released by Anacor
  • 12 Oct 2011 Anacor Pharmaceuticals completes enrolment in its phase II trial for Atopic dermatitis in Australia (NCT01301508)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top